Literature DB >> 12972481

Renal artery stenosis in the antiphospholipid (Hughes) syndrome and hypertension.

S R Sangle1, D P D'Cruz, W Jan, M Y Karim, M A Khamashta, I C Abbs, G R V Hughes.   

Abstract

BACKGROUND: Hypertension is common in the antiphospholipid (Hughes) syndrome (APS) and its cause is poorly understood. Anecdotal evidence suggests that renal artery stenosis (RAS) may be a relevant and treatable cause of hypertension.
OBJECTIVE: To investigate the prevalence of RAS in patients with APS and hypertension. PATIENTS AND METHODS: Three groups of patients were evaluated: (1) 77 patients with positive antiphospholipid antibodies (aPL) (60 secondary APS, 11 primary APS, and 6 with aPL only) and uncontrolled hypertension who were receiving two or more antihypertensive drugs; (2) 91 patients (</=50 years) attending hypertension clinics;(3) 92 normotensive healthy, potential renal transplant donors. Magnetic resonance renal angiography was used to image the renal arteries in all three groups.
RESULTS: Group 1: 20/77 (26%) patients had evidence of RAS (16 unilateral and 4 bilateral). Sixteen patients (80%) had smooth well defined stenoses in the proximal third of the renal artery. Three further patients had irregular arteries without distinct stenosis. Group 2: 7/91 (8%) hypertensive patients had RAS (chi(2)=10.3, p<0.001 v group 1). Group 3: 3/92 (3%) healthy donors had RAS (chi(2)=18.2, p<0.0001 v group 1).
CONCLUSION: A significantly increased prevalence of RAS (26%) was found in patients with APS and hypertension, compared with relatively young (</=50 years) hypertensive controls and healthy potential donors.

Entities:  

Mesh:

Year:  2003        PMID: 12972481      PMCID: PMC1754312          DOI: 10.1136/ard.62.10.999

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  22 in total

Review 1.  Renovascular hypertension: screening and modern management.

Authors:  Iris Baumgartner; Lilach O Lerman
Journal:  Eur Heart J       Date:  2011-01-27       Impact factor: 29.983

2.  Hughes syndrome (the antiphospholipid syndrome): a disease of our time.

Authors:  Graham R V Hughes
Journal:  Inflammopharmacology       Date:  2010-12-05       Impact factor: 4.473

3.  The treatment of lupus nephritis.

Authors:  David P D'Cruz; Graham R V Hughes
Journal:  BMJ       Date:  2005-02-19

Review 4.  Systemic lupus erythematosus.

Authors:  David P D'Cruz
Journal:  BMJ       Date:  2006-04-15

5.  Treatment of mesenteric angina with prolonged anticoagulation in a patient with antiphospholipid (Hughes) syndrome and coeliac artery stenosis.

Authors:  E Rosenthal; S R Sangle; P Taylor; M A Khamashta; G R V Hughes; D P D'Cruz
Journal:  Ann Rheum Dis       Date:  2006-10       Impact factor: 19.103

6.  Antiphospholipid antibodies attenuate endothelial repair and promote neointima formation in mice.

Authors:  Victoria Ulrich; Eddy S Konaniah; Wan-Ru Lee; Sadiksha Khadka; Yu-Min Shen; Joachim Herz; Jane E Salmon; David Y Hui; Philip W Shaul; Chieko Mineo
Journal:  J Am Heart Assoc       Date:  2014-10-14       Impact factor: 5.501

Review 7.  Renal involvement in antiphospholipid syndrome.

Authors:  Guillermo J Pons-Estel; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

Review 8.  Vascular Manifestations in Antiphospholipid Syndrome (APS): Is APS a Thrombophilia or a Vasculopathy?

Authors:  Salma Siddique; Jessie Risse; Guillaume Canaud; Stéphane Zuily
Journal:  Curr Rheumatol Rep       Date:  2017-09-04       Impact factor: 4.592

Review 9.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 10.  Renal involvement in the antiphospholipid syndrome (APS)-APS nephropathy.

Authors:  Maria G Tektonidou
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.